Jiangsu, China

Lin Wang

USPTO Granted Patents = 7 

Average Co-Inventor Count = 4.4

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
7 patents (USPTO):

Title: Lin Wang: Innovator in Cancer Treatment Technologies

Introduction

Lin Wang is a prominent inventor based in Jiangsu, China, known for his significant contributions to the field of cancer treatment technologies. With a total of seven patents to his name, Wang has made remarkable strides in developing innovative solutions that target cancer cells effectively.

Latest Patents

Among his latest patents is the development of chimeric antigen receptors targeting BCMA. This application provides single-domain antibodies that specifically target BCMA, along with chimeric antigen receptors, including monovalent and multivalent CARs. These advancements also encompass engineered immune effector cells, such as T cells, that incorporate these chimeric antigen receptors. Additionally, Wang has patented a crystal form of a pyridopyrimidine derivative, which includes a preparation method that enhances the compound's physical and chemical properties, thereby facilitating clinical treatments.

Career Highlights

Lin Wang has worked with notable companies, including Inspur Suzhou Intelligent Technology Co., Ltd and Suzhou Metabrain Intelligent Technology Co., Ltd. His work in these organizations has allowed him to apply his innovative ideas in practical settings, contributing to advancements in intelligent technology and healthcare.

Collaborations

Wang has collaborated with talented individuals in his field, including Ruizhen Wu and Jingjing Chen, who have contributed to his research and development efforts.

Conclusion

Lin Wang's innovative work in cancer treatment technologies showcases his dedication to improving healthcare through scientific advancements. His patents reflect a commitment to developing effective solutions for complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…